Mycenax Biotech (4726) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.031x

Based on the latest financial reports, Mycenax Biotech (4726) has a cash flow conversion efficiency ratio of -0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-50.35 Million ≈ $-1.59 Million USD) by net assets (NT$1.64 Billion ≈ $51.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Mycenax Biotech (4726) total market value for the company's overall valuation and market capitalisation.

Mycenax Biotech - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Mycenax Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Mycenax Biotech Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mycenax Biotech ranked by their cash flow conversion efficiency. Explore how high is Mycenax Biotech's earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Jochu Technology Co Ltd TW:3543	-0.065x
HLB Pharmaceutical Co. Ltd KQ:047920	0.015x
CYGNUS Metals Ltd AU:CY5	-0.033x
Asia Plus Group Holdings PCL BK:ASP	0.253x
Dazhong Transportation Group Co Ltd B SHG:900903	0.000x
Jaya Agra Wattie Tbk JK:JAWA	0.023x
Purple Capital Ltd JSE:PPE	0.014x
EUROZ Hartleys Group Ltd AU:EZL	0.132x

Annual Cash Flow Conversion Efficiency for Mycenax Biotech (2017–2024)

The table below shows the annual cash flow conversion efficiency of Mycenax Biotech from 2017 to 2024. View Mycenax Biotech (4726) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$2.02 Billion ≈ $63.75 Million	NT$-191.68 Million ≈ $-6.04 Million	-0.095x	-76.72%
2023-12-31	NT$2.45 Billion ≈ $77.10 Million	NT$-131.18 Million ≈ $-4.13 Million	-0.054x	-10.84%
2022-12-31	NT$3.11 Billion ≈ $97.84 Million	NT$-150.19 Million ≈ $-4.73 Million	-0.048x	+36.95%
2021-12-31	NT$1.91 Billion ≈ $60.07 Million	NT$-146.23 Million ≈ $-4.61 Million	-0.077x	-153.36%
2020-12-31	NT$1.21 Billion ≈ $38.17 Million	NT$174.17 Million ≈ $5.49 Million	0.144x	+212.55%
2019-12-31	NT$1.10 Billion ≈ $34.72 Million	NT$-140.74 Million ≈ $-4.43 Million	-0.128x	+35.74%
2018-12-31	NT$907.01 Million ≈ $28.58 Million	NT$-180.27 Million ≈ $-5.68 Million	-0.199x	-399.11%
2017-12-31	NT$1.14 Billion ≈ $36.04 Million	NT$-45.55 Million ≈ $-1.44 Million	-0.040x	--

About Mycenax Biotech

TWO:4726 Taiwan Biotechnology

Market Cap

$146.62 Million

NT$4.65 Billion TWD

Market Cap Rank

#17810 Global

#910 in Taiwan

Share Price

NT$22.45

Change (1 day)

-0.66%

52-Week Range

NT$22.45 - NT$37.95

All Time High

NT$68.00